Mission Wealth Management LP Acquires Shares of 9,583 Structure Therapeutics Inc. Sponsored ADR $GPCR

Mission Wealth Management LP acquired a new stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 9,583 shares of the company’s stock, valued at approximately $268,000.

Several other hedge funds and other institutional investors have also modified their holdings of GPCR. State of Wyoming acquired a new position in Structure Therapeutics in the 2nd quarter valued at about $28,000. Assetmark Inc. boosted its holdings in shares of Structure Therapeutics by 39.9% during the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after acquiring an additional 820 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Structure Therapeutics by 29.1% in the second quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after purchasing an additional 994 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Structure Therapeutics during the second quarter worth approximately $129,000. Finally, DNB Asset Management AS acquired a new stake in Structure Therapeutics during the 2nd quarter worth approximately $221,000. Institutional investors own 91.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on GPCR. Jefferies Financial Group set a $125.00 price objective on Structure Therapeutics and gave the company a “buy” rating in a report on Thursday, December 11th. Zacks Research downgraded shares of Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, October 17th. Citizens Jmp lifted their price objective on shares of Structure Therapeutics from $87.00 to $120.00 and gave the stock a “market outperform” rating in a research note on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. lifted their price target on shares of Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $104.45.

Structure Therapeutics Stock Down 9.9%

Shares of Structure Therapeutics stock opened at $73.21 on Friday. Structure Therapeutics Inc. Sponsored ADR has a 12-month low of $13.22 and a 12-month high of $94.90. The company has a market capitalization of $4.44 billion, a price-to-earnings ratio of -60.01 and a beta of -2.06. The firm’s 50-day moving average price is $70.03 and its two-hundred day moving average price is $40.67.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.01). On average, sell-side analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.